Stock HNSA HANSA BIOPHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Hansa Biopharma AB

Equities

HNSA

SE0002148817

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:32 2024-05-23 am EDT 		5-day change 1st Jan Change
43.62 SEK +3.02% Intraday chart for Hansa Biopharma AB +14.79% +66.49%
Apr. 18 Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
Apr. 18 Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
AQ
Correction, Hansa Biopharma, increase in number of shares and votes
AQ
Correction: Hansa Biopharma: increase in number of shares and votes
PU
Hansa Biopharma: increase in number of shares and votes
AQ
Hansa Biopharma Q1 - Improved European launch support
AQ
Hansa Biopharma interim report January-March 2024
AQ
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)
AQ
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
AQ
Hansa Biopharma publishes 2023 Annual and Sustainability Reports
AQ
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
AQ
Hansa Biopharma - Improved sales prospects
AQ
Hansa Biopharma Year-end report January-December 2023
AQ
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
AQ
Hansa Biopharma - Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation
AQ
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation
AQ
Hansa Biopharma Nomination Committee formed
AQ
Hansa Biopharma - Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 Trial in Guillain-Barre Syndrome
AQ
Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)
AQ
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables
AQ
Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HNSA Stock
  4. News Hansa Biopharma AB
  5. Press Releases